Why the study?
Does bivalirudin alone reduce 30-day rates of major bleeding and net adverse clinical events in patients with ST-segment elevation myocardial infarction who are undergoing primary PCI?
Does bivalirudin alone reduce 30-day rates of major bleeding and net adverse clinical events in patients with ST-segment elevation myocardial infarction who are undergoing primary PCI?
In STEMI patients undergoing primary PCI, bivalirudin alone significantly reduces 30-day major bleeding and net adverse clinical events compared to heparin plus glycoprotein IIb/IIIa inhibitors.
Supports bivalirudin monotherapy in STEMI primary PCI; confirms net clinical benefit over heparin plus GP IIb/IIIa inhibitors.
In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, NCT00433966 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Stone et al. (2008) studied this question.